Infections and Infectious Diseases | Drugs in Discovery

AbCellera

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

9th Annual HPAPI Summit 2020

Participation Not Confirmed

Update your events

AbCellera Announces Multi-Year Antibody Discovery Collaboration with Lilly

Lead Product(s): Antibodies

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Eli Lilly

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 22, 2020

Details:

AbCellera will use its world-leading antibody drug discovery platform in a multi-year collaboration to identify antibodies against up to nine targets.

Atomwise

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

9th Annual HPAPI Summit 2020

Participation Not Confirmed

Update your events

Atomwise Partners with Global Research Teams to Pursue Broad-Spectrum Treatments Against COVID-19 and Future Coronavirus Outbreaks

Lead Product(s): Undisclosed

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership May 21, 2020

Details:

Atomwise democratizes access to its advanced AI technology with 15 research collaborations underway to enable academic researchers to discover novel therapies for this pandemic and those in the future.

Shionogi Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

9th Annual HPAPI Summit 2020

Participation Not Confirmed

Update your events

Shionogi to Develop Prophylactic Vaccine for COVID-19

Lead Product(s): Prophylactic recombinant protein vaccine

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Discovery Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 18, 2020

Details:

In a project supported by the Japan Agency for Medical Research and Development (AMED), Shionogi and its subsidiary, UMN Pharma, are pursuing the discovery and development of a recombinant protein vaccine for COVID-19, using their unique technology.

Abcore

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

9th Annual HPAPI Summit 2020

Participation Not Confirmed

Update your events

Abcore Announces a Panel of Patent Pending Functional Single Domain Antibodies for Use as Therapeutic Candidates for Treatment of COVID-19

Lead Product(s): Single domain antibodies

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 18, 2020

Details:

Abcore has demonstrated these therapeutic candidates bind to the spike protein of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and functionally block binding to the Angiotensin Converting Enzyme-2 (ACE2) receptor.

IDBiologics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

9th Annual HPAPI Summit 2020

Participation Not Confirmed

Update your events

Vanderbilt University Medical Center and IDBiologics Ally in Race to Develop Breakthrough Medicines for COVID-19

Lead Product(s): Monoclonal antibody

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Vanderbilt University Medical Center

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 07, 2020

Details:

For assessment and future licensing and clinical development, certain monoclonal antibodies discovered in Dr. James Crowe's laboratory at the Vanderbilt Vaccine Center will be shared with IDBiologics.

Atreca

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

9th Annual HPAPI Summit 2020

Participation Not Confirmed

Update your events

Atreca, BeiGene, and IGM Biosciences Agree to Collaborate on Novel Antibody Treatment for COVID-19

Lead Product(s): IgM antibodies

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: BeiGene

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 29, 2020

Details:

The companies will leverage their combined technology in an effort to discover, develop, and manufacture novel IgM and IgA antibodies targeting SARS-CoV-2 for the potential treatment of COVID-19.

Secarna Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

9th Annual HPAPI Summit 2020

Participation Not Confirmed

Update your events

Secarna Pharmaceuticals Enters into Cooperation with Guangzhou’s Sun Yat-sen University to Develop a Treatment for SARS-CoV-2

Lead Product(s): Antisense oligonucleotides

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Guangzhou’s Sun Yat-sen University

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 28, 2020

Details:

Under this agreement, Secarna will employ its proprietary LNAplusTM platform to develop antisense oligonucleotides (ASOs) which specifically suppress the expression of a certain host factor that is essential for the viral infection cycle.

ImmunoPrecise

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

9th Annual HPAPI Summit 2020

Participation Not Confirmed

Update your events

ImmunoPrecise Awarded Grant Focused on Coronavirus and Other Emerging Pathogens

Lead Product(s): Monocloncal antibodies

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: State of North Dakota

Deal Size: $0.1 million Upfront Cash: Undisclosed

Deal Type: Funding April 24, 2020

Details:

The State of North Dakota has provided ImmunoPrecise grant for the development of a novel platform for the rapid development of COVID-19 drugs and other emerging pathogens.